Skip to main content
    S

    Syndax Pharmaceuticals Inc (SNDX)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $13.95
    -2.60 (-15.71%)

    Market Cap: $1.25B

    Last updated: Oct 16, 2026 at 1:55 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    77%(30/39)
    Avg Surprise
    +11.44%

    Upcoming Estimates

    Period ending Sep 30, 2026
    EPS Consensus$-0.48
    Range$-0.58 - $-0.31
    10 analysts
    EPS Revisions
    3
    0
    7d
    3
    6
    30d
    EPS Estimate DriftChange to current
    90d ago$-0.40-20.1%
    60d ago$-0.36-31.0%
    30d ago$-0.47-1.1%
    7d ago$-0.47-1.1%
    Current$-0.48
    Revenue Consensus
    $82M
    Range$79M - $86M
    11 analysts
    Period ending Dec 31, 2026
    EPS Consensus$-0.45
    Range$-0.75 - $-0.15
    10 analysts
    Revenue Consensus
    $83M
    Range$72M - $103M
    11 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$-0.45---
    Sep 26EST
    		-$-0.48---
    Jun 26
    Reported Aug 4
    		$-0.55$-0.45-22.22%Miss+33.7%
    Mar 26
    Reported Apr 30
    		$-0.48$-0.59+18.64%Beat+51.0%
    Dec 25
    Reported Feb 26
    		$-0.78$-0.64-21.88%Miss+29.1%
    Sep 25
    Reported Nov 3
    		$-0.70$-0.71+1.41%Beat+28.6%
    Jun 25
    Reported Aug 4
    		$-0.83$-1.01+17.82%Beat-3.7%
    Mar 25
    Reported May 5
    		$-0.98$-1.27+22.83%Beat-15.3%
    Dec 24
    Reported Mar 3
    		$-1.10$-0.23-380.56%Miss-10.0%
    Sep 24
    Reported Nov 5
    		$-0.98$-1.06+7.55%Beat-34.2%
    Jun 24
    Reported Aug 1
    		$-0.80$-0.91+12.09%Beat-25.0%
    Mar 24
    Reported May 8
    		$-0.85$-0.98+13.27%Beat-44.1%
    Dec 23
    Reported Feb 27
    		$-1.00$-0.97-3.09%Miss-61.3%
    Sep 23
    Reported Nov 2
    		$-0.73$-0.80+8.75%Beat-25.9%
    Jun 23
    Reported Aug 3
    		$-0.64$-0.75+14.67%Beat-3.2%
    Mar 23
    Reported May 8
    		$-0.59$-0.61+3.28%Beat+6.3%
    Dec 22
    Reported Feb 28
    		$-0.62$-0.65+4.62%Beat-134.3%
    Sep 22
    Reported Nov 3
    		$-0.58$-0.63+7.94%Beat-45.0%
    Jun 22
    Reported Aug 8
    		$-0.62$-0.62+0.00%Beat-40.9%
    Mar 22
    Reported May 9
    		$-0.63$-0.68+7.35%Beat-16.7%
    Dec 21
    Reported Mar 1
    		$1.81$0.28+546.43%Beat+511.4%
    Sep 21
    Reported Nov 15
    		$-0.40$-0.57+29.82%Beat+13.0%
    Jun 21
    Reported Aug 9
    		$-0.44$-0.73+39.73%Beat-4.8%
    Mar 21
    Reported May 11
    		$-0.54$-0.64+15.63%Beat+3.6%
    Dec 20
    Reported Mar 8
    		$-0.44$-0.49+10.20%Beat+0.0%
    Sep 20
    Reported Nov 2
    		$-0.46$-0.43-6.98%Miss-12.2%
    Jun 20
    Reported Aug 6
    		$-0.42$-0.44+4.55%Beat+10.6%
    Mar 20
    Reported May 7
    		$-0.56$-0.51-9.80%Miss-5.7%
    Dec 19
    Reported Mar 3
    		$-0.44$-0.43-2.33%Miss+37.1%
    Sep 19
    Reported Nov 7
    		$-0.41$-0.48+14.58%Beat+39.7%
    Jun 19
    Reported Aug 7
    		$-0.47$-0.47+0.00%Beat+36.5%
    Mar 19
    Reported May 6
    		$-0.53$-0.55+3.64%Beat+32.9%
    Dec 18
    Reported Mar 7
    		$-0.70$-0.67-4.48%Miss+12.5%
    Sep 18
    Reported Nov 5
    		$-0.68$-0.76+10.53%Beat+0.0%
    Jun 18
    Reported Aug 7
    		$-0.74$-0.89+16.85%Beat-5.7%
    Mar 18
    Reported May 8
    		$-0.79$-0.95+16.84%Beat-11.3%
    Dec 17
    Reported Mar 5
    		$-0.80$-0.78-2.56%Miss-35.6%
    Sep 17
    Reported Nov 7
    		$-0.68$-0.82+17.07%Beat-
    Jun 17
    Reported Aug 10
    		$-0.70$-0.82+14.63%Beat-
    Mar 17
    Reported May 8
    		$-0.71$-0.71+0.00%Beat-
    Dec 16
    Reported Mar 2
    		$-0.59$-0.73+19.18%Beat-

    Key Metrics

    Valuation
    P/E Ratio-5.56EV/EBITDAN/A
    Price/FCFN/AFCF YieldN/A
    Profitability
    Profit Margin-87.50%Operating Margin-54.90%
    ROE-255.90%ROIC-60.64%
    Financial Health
    Debt/Equity16.22xInterest CoverageN/A
    Current Ratio6.77xQuick Ratio6.44x
    Trading Statistics
    Beta0.42Avg Volume2.14M
    52-Week High$25.5952-Week Low$12.99

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$17.12
    SMA 20$17.50
    SMA 50$18.85
    SMA 200$20.72
    EMA 10$16.72
    EMA 20$17.44
    EMA 50$18.56
    EMA 200$19.33

    MACD

    Line: -0.84Signal: -0.59Hist: -0.25

    ADX

    ADX: 34.6+DI: 8.7-DI: 44.6

    Aroon & PSAR

    Aroon UpN/A
    Aroon Down100.0
    PSAR$18.53

    Bollinger Bands

    Upper Band$19.50
    Lower Band$15.50
    %B Position2285%(Upper)
    Band Width-0.39

    RSI (14-Day)

    Oversold
    22.4

    Momentum Oscillators

    Stoch %K13.0
    Stoch %D15.7
    Williams %R-91.6
    ROC (10d)-23.5%
    Momentum-4.29
    CCI (20d)-395.4
    MFI (14d)30.0

    Volatility Measures

    ATR (14d)$0.96(6.9%)
    StdDev (20d)1.00
    Hist Vol65.4%(High)

    Volume Flow

    VWAP$14.06
    OBV16.5M
    AD Line-30.0M
    CMF (20d)-0.139

    Volume Metrics

    Avg Vol (20d)2.2M
    Vol Ratio3.0x(High)
    VWMA (20d)$17.09

    Pivot Points

    R3$17.46
    R2$17.20
    R1$16.88
    Pivot Point$16.62
    S1$16.30
    S2$16.04
    S3$15.72

    Advanced Oscillators

    TSI-28.29
    Ultimate Osc32.7
    KST-101.84

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$72.79M$64.86M$68.48M$45.87M$37.96M$20.04M$7.68M$12.50M$3.50M$0$536,000$0
    Cost of Revenue$3.21M$2.63M$2.71M$2.10M$1.28M$885,000$826,000$0$0$0$268,000$0
    Gross Profit$69.58M$62.23M$65.78M$43.77M$36.68M$19.16M$6.85M$12.50M$3.50M$0$268,000$0
    Operating Expenses$109.58M$96.43M$128.32M$101.20M$106.03M$102.91M$103.22M$102.08M$77.72M$79.51M$77.91M$56.35M
    R&D$68.04M$58.84M$78.64M$56.28M$62.23M$61.64M$65.53M$70.97M$48.66M$56.49M$55.13M$39.09M
    SG&A$41.54M$37.59M$49.93M$44.92M$43.80M$41.03M$37.69M$31.11M$29.06M$23.02M$22.78M$17.27M
    Operating Income$-39,995,000$-34,202,000$-62,548,000$-57,426,000$-69,353,000$-83,757,000$-96,365,000$-89,577,000$-74,216,000$-79,514,000$-77,906,000$-56,355,000
    Interest Income$3.75M$3.56M$4.33M$5.27M$5.95M$7.18M$7.11M$5.44M$6.28M$7.26M$5.55M$5.34M
    Interest Expense$557,000$11.85M$25.73M$0$4,000$8.05M$-124,000$23,000$45,000$55,000$63,000$70,000
    Income Before Tax$-49,363,000$-42,673,000$-68,014,000$-60,715,000$-71,847,000$-84,846,000$-94,169,000$-84,126,000$-68,063,000$-72,400,000$-72,473,000$-51,146,000
    Income Tax Expense$0$0$0$0$0$0$0$0$0$0$0$0
    Net Income$-49,363,000$-42,673,000$-68,014,000$-60,715,000$-71,847,000$-84,846,000$-94,169,000$-84,126,000$-68,063,000$-72,400,000$-72,473,000$-51,146,000
    EBITDA$-52,950,000$-35,190,000$-48,140,000$-68,335,000$-80,949,000$-87,465,000$-104,311,000$-92,603,000$-77,951,000$-83,422,000$-81,420,000$-60,080,000
    EBIT$-52,552,000$-34,388,000$-46,612,000$-65,984,000$-77,793,000$-83,978,000$-101,401,000$-89,545,000$-74,302,000$-79,601,000$-77,961,000$-56,421,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about SNDX

    News

    Syndax Pharmaceuticals stock hits 52-week low at 12.98 USD By Investing.com

    Syndax Pharmaceuticals (SNDX) stock has fallen to a 52-week low of $12.98, experiencing a nearly 20% decline in the past week and an 8.53% drop over the year. Despite this...

    Investing.com India•10/16/26•Bearish

    Syndax’s Revuforj® (revumenib) Named to TIME’s Best Inventions of 2026 List

    Syndax Pharmaceuticals announced that its first-in-class menin inhibitor, Revuforj (revumenib), was selected by TIME as one of the "Best Inventions of 2026" in the Medical and Healthcare category. Revuforj is...

    GlobeNewswire•10/15/26•Bullish

    HC Wainwright keeps USD 38.00 target for Syndax Pharmaceuticals stock

    HC Wainwright has maintained its USD 38.00 price target for Syndax Pharmaceuticals (SNDX) despite the company reporting a setback in its MAXPIRe Phase 2 trial for axatilimab. The clinical trial for idiopathic pulmonary...

    ad-hoc-news.de•10/15/26•Somewhat-Bearish

    Syndax Pharmaceuticals, Inc. (SNDX) Securities Fraud Investigation - Levi & Korsinsky

    Levi & Korsinsky has initiated an investigation into Syndax Pharmaceuticals, Inc. (SNDX) regarding potential federal securities law violations. This follows a 15.71% drop in Syndax shares after its Phase 2 MAXPIRe trial...

    ACCESS Newswire•10/14/26•Bearish

    Syndax Pharmaceuticals (SNDX) Stock Dropped, So What Is Behind The Move?

    Syndax Pharmaceuticals (SNDX) shares dropped after its MAXPIRe Phase 2 trial for axatilimab in idiopathic pulmonary fibrosis missed its primary endpoint...

    Simply Wall Street•10/14/26•Somewhat-Bearish

    SNDX Valuation and Fair Value

    P/E
    -5.6x
    PEG
    0.0x
    P/B
    82.2x
    See GNG's fair value

    SNDX Profitability: Margins, ROIC and FCF

    Gross margin
    95.8%
    Operating margin
    -54.9%
    Net margin
    -87.5%
    ROIC
    -60.6%
    ROE
    -255.9%
    FCF margin
    -87.6%

    SNDX Competitors

    CompanyTicker
    Inhibrx Biosciences, Inc.INBX
    InnovAge Holding CorpINNV
    Nektar TherapeuticsNKTR
    Tourmaline Bio Inc.TRML
    U.S. Physical Therapy, Inc.USPH
    Oric Pharmaceuticals IncORIC
    Tyra Biosciences IncTYRA
    CareCloud, Inc.CCLDO

    Sector: Healthcare

    SNDX Analyst Ratings

    Consensus
    Buy
    Analysts
    12
    Strong Buy
    2
    Buy
    10
    Hold
    0
    Sell
    0
    Strong Sell
    0

    SNDX Bull Case vs Bear Case

    Bull case

    • SNDX grew quarterly revenue 91.8% year over year.
    • 100.0% of SNDX's analyst ratings are Buy or Strong Buy.

    Bear case

    • SNDX has a -87.5% net profit margin.
    • SNDX has a debt-to-equity ratio of 16.2x.

    SNDX Earnings: Beat Rate and Next Report

    Beat rate
    5 of 8 quarters (62.5%)
    Average surprise
    -44.6%
    EPS estimate (fiscal period ending Sep 30, 2026)
    $-0.48
    Estimate revisions (30 days, fiscal period ending Sep 30, 2026)
    3 up, 6 down

    Frequently Asked Questions About SNDX

    Does SNDX pay dividends?

    Syndax Pharmaceuticals Inc (SNDX) does not currently pay a regular dividend.

    What is SNDX's market cap?

    Syndax Pharmaceuticals Inc (SNDX) has a market capitalization of $1.25B with a current stock price of $13.95.

    Related stocks

    Sector: Healthcare

    All stocks starting with S

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In